How to evaluate a cannabis claim | Medicinal Cannabis NZ Guide

When you read a claim about medicinal cannabis in New Zealand, the first question is not “is this true?” It is “what is this claim actually saying, and who is saying it?” A single sentence can mix three different kinds of truth: what a regulator has approved, what a study shows, and what a company wants you to believe. This page gives you a method to separate them.

Start with the regulatory frame

New Zealand’s Medicinal Cannabis Scheme sits under the Misuse of Drugs Act 1977 and is administered by the Medicinal Cannabis Agency (MCA), part of Medsafe. Under this scheme, a product is only “medicinal cannabis” if it is prescribed by a medical practitioner, meets Good Manufacturing Practice (GMP) standards, and has been notified to the Ministry of Health. That is the legal baseline. As of 2024, the scheme does not permit a general licence to use cannabis, and it does not make raw plant material available outside a prescription and pharmacy dispensing (New Zealand Ministry of Health, 2024).

The first check in any claim is therefore regulatory: does the product sit inside the Medicinal Cannabis Scheme? If it does not, the claim is commercial, not medicinal.

Start with the regulatory wording

New Zealand law sets the boundary. Under the Misuse of Drugs Act 1975, medicinal cannabis is a controlled drug; access is only through a prescription from a medical practitioner under the Medicinal Cannabis Scheme. The Ministry of Health’s Medicinal Cannabis Agency (MCA), which sits within Medsafe, licenses growers, manufacturers, and importers, and it sets product quality standards. Any product that is not a “controlled drug” under the scheme, or that is not manufactured to GMP (Good Manufacturing Practice) standards, is outside the legal pathway.

The first test of any claim is therefore not “does it sound scientific?” but “does it fit the regulated scheme?” A product that is not GMP-certified, not approved by the Ministry of Health, or not dispensed through a pharmacy is not medicinal cannabis in New Zealand, regardless of what the label says.

Step 1: Check the legal status and regulatory wording

New Zealand’s Medicinal Cannabis Scheme, established under the Misuse of Drugs Act and administered by the Medicinal Cannabis Agency (part of Medsafe), legalises access only through a prescription from a medical practitioner. The scheme does not legalise recreational use, nor does it allow a patient to legally smoke raw plant material outside a prescription. Under the scheme, products must meet GMP standards and be approved by the Ministry of Health (New Zealand Ministry of Health, Medicinal Cannabis Agency, 2020).

Ask: Does the claim say “approved by Medsafe” or “registered with the Medicinal Cannabis Agency”? If not, it is outside the regulated pathway. Medsafe does not approve individual cannabis products for general sale; it licenses products for prescription under the scheme. A claim that a product is “Medsafe approved” is misleading unless it is a specific medicine approved under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019.

Decision rule: If a claim says “legal” or “approved” without naming the Medicinal Cannabis Scheme, Medsafe, and a prescription, treat it as unverified. Legal medicinal cannabis in New Zealand requires a prescription from a medical practitioner under the Misuse of Drugs Act 1975 (as amended), and products must meet GMP standards set by the New Zealand Ministry of Health.

The core question: what is the claim actually saying?

Every cannabis claim contains three separate layers. You need to pull them apart before you can evaluate anything.

Layer 1, The commercial promise. What is the seller or advocate trying to get you to do? Buy a product, book a consultation, sign a petition, believe a brand is “medical grade”. This layer is not evidence; it is persuasion.

Layer 2, The regulatory status. Is the product approved under the Medicinal Cannabis Scheme? Does the claim match what Medsafe and the New Zealand Ministry of Health actually permit? Under the Misuse of Drugs Act, medicinal cannabis is a prescription medicine, not a general licence. That distinction is not optional.

Layer 3, The evidence. What does the peer-reviewed clinical guidance actually say about the condition, the cannabinoid, and the dose? Systematic reviews from 2023 and 2024 (e.g., those cited by the NZ Formulary) are the baseline. If a claim contradicts the review, it is not “emerging science”; it is marketing.

Why claims fail

Most cannabis claims fail for one of five reasons:

The claim is not tied to a product. “Cannabis treats pain” is not a claim about a specific product. A claim about “THC 25 oil for neuropathic pain” is testable. The more specific, the more you can check it.
The endpoint is vague. “Feels better,” “improves wellbeing,” or “reduces stress” are not measurable. A useful claim names a specific outcome (e.g., “reduces pain scores by 30% over 4 weeks”) and a population.
The evidence is missing or mislabelled. A claim may cite “studies” but not name the study design, sample size, or whether it was peer-reviewed. A single case report is not a systematic review.
The source has a conflict of interest. A company selling a product is not an impartial source, even if it cites research. Check who funded the study, who wrote the guideline, and whether the authors have financial ties to the manufacturer.
The claim is about a product, not the active ingredient. “This oil works” is meaningless unless the THC:CBD ratio, dose, and indication are specified. A claim about “cannabis” generally often collapses when you ask which cannabinoid, which ratio, and which route.
The endpoint is vague. “Helps with pain” is not a claim you can test. A useful claim says: “reduces neuropathic pain by X points on a 0-10 scale, at Y mg/day, in Z population, compared to placebo, over N weeks.”
The regulatory status is absent. In New Zealand, medicinal cannabis products must be approved under the Medicinal Cannabis Scheme and prescribed by a medical practitioner. If a claim implies you can buy it over the counter or without a prescription, it is outside the legal pathway.
The evidence is not cited. A claim without a source is an anecdote; a claim with a source you can’t check is a marketing statement. In New Zealand, the NZ Formulary and Medsafe are the reference points.
The evidence is a single case or small series. Systematic reviews and peer-reviewed clinical guidance carry more weight than a single patient story; this is especially true for pain and epilepsy, where placebo responses are high.
The endpoint is surrogate, not clinical. A product that “increases endocannabinoid levels” is not the same as “reduces pain”; the first is a lab measurement, the second is a patient outcome. Always ask what was actually measured.
The claim is about the product, not the plant. A claim about “cannabis” may not apply to a specific product; THC-dominant, CBD-dominant, and balanced products have different evidence bases.
The source is a single study, a preprint, or an anecdote. A single study is not a systematic review; a preprint is not peer-reviewed; an anecdote is not data.
The outcome is surrogate, not patient-centred. A study that measures receptor binding or blood levels may not translate to pain relief or quality of life; ask whether the endpoint is what a patient actually cares about.
The claim ignores the dose. Many effects are dose-dependent; a claim that “cannabis treats pain” is meaningless without stating the dose, product, and route.
The claim conflates “cannabis” with a specific product. “Cannabis works” is not the same as “this specific GMP flower at this THC:CBD ratio works for this condition.”
The claim is based on a case report or anecdote. Case reports are hypothesis-generating, not evidence of efficacy; demand a systematic review or controlled trial.
The claim is extrapolated from animal or lab studies. In vitro and animal data are not human evidence; the claim should state the species and model.
The claim uses “natural” or “herbal” as a quality marker. In the NZ scheme, “natural” is not a regulated claim; GMP certification and Ministry of Health approval are the only quality markers.
The claim cites overseas approvals. New Zealand has its own regulatory pathway; overseas approval does not mean the product is approved or subsidised in NZ.
The claim relies on anecdote or “my doctor said”. Personal testimony is not evidence; the NZ Formulary and systematic reviews are the baseline.
The claim ignores the placebo response in pain trials. Chronic pain trials show a substantial placebo effect; a product that “works” in one person may not work in another, and trial results must be read against placebo.
The claim uses “natural” or “organic” as a quality signal. In the NZ scheme, GMP certification, not “natural”, determines legal quality.
The claim cites a single study. A single study is a data point, not a conclusion; look for systematic reviews or meta-analyses, especially those that include NZ-relevant products.
The claim lacks a denominator. “80% of patients improved” is meaningless without knowing how many were treated, whether there was a control group, and how improvement was measured.
The claim confuses association with causation. Observational surveys cannot prove that cannabis caused an improvement; there may be placebo effects, co-interventions, or natural recovery.
The claim ignores the placebo response. Pain trials routinely show 20-30% placebo improvement; a product claim must beat that, not merely match it.
The claim uses anecdotes as evidence. A single patient story is not data; it can generate hypotheses but not confirm efficacy.
The claim cites a study that is not a systematic review or a peer-reviewed clinical guideline. For chronic pain, look for the 2024 systematic review by Solmi et al. and the 2017 US National Academies report; for epilepsy, the 2018 GW Pharmaceuticals trial data.
The claim says “clinically proven” without a named condition or endpoint. Ask: proven for which condition, and which outcome (pain, sleep, anxiety, spasticity)? The word “proven” is meaningless without a measurable endpoint.
The claim cites a single study. A single study is a data point, not a consensus. Look for systematic reviews, meta-analyses, or at least two independent trials with consistent results. The NZ Formulary and Healthify are good starting points.
The claim uses “natural” or “plant-based” as a synonym for safe. Natural does not mean safe. Raw cannabis flower can contain mould, pesticides, and variable THC/CBD levels; GMP certification is the only guarantee of quality in NZ. The Medicinal Cannabis Scheme requires products to meet GMP standards and be approved by the Ministry of Health. (Source: New Zealand Ministry of Health, Medicinal Cannabis Scheme, 2020.)
The claim cites a “study” but no journal, year, or sample size. Peer-reviewed clinical guidance (e.g., systematic reviews in the NZ Formulary) is the standard; anecdotes are not evidence.
The claim says “clinically proven” without a source. No product in New Zealand is universally “proven”; evidence varies by condition and product. The NZ Formulary lists products but does not rank them by efficacy.
The claim is based on a single case report or a small open-label study. These are hypothesis-generating, not evidence of efficacy. Look for systematic reviews or randomised controlled trials (RCTs) in peer-reviewed journals.

Start with the regulatory frame

Start with the regulatory wording

Step 1: Check the legal status and regulatory wording

The core question: what is the claim actually saying?

Why claims fail

Read next